Somavert and neoplasm progression Patient Reports February 11, 2012
Somavert Side Effects Report #4608820-5
Somavert side effect was reported by a Physician from on Feb 28, 2005. Female patient, 63 years of age, weighting 123.5 lb, was diagnosed with acromegaly and was treated with Somavert. After drug was administered, patient experienced the following side effects: adenoma benign, headache
, neoplasm progression. Somavert dosage: 10 MG (10 MG, DAILY), SUBCUTANEOUS. Patient was hospitalized. Patient recovered.Somavert Side Effects Report #4947461-7
Somavert side effect was reported by a Physician from BELGIUM on Nov 17, 2004. Female patient, 61 years of age, weighting 159.8 lb, was diagnosed with acromegaly and was treated with Somavert. After drug was administered, patient experienced the following side effects: headache
, laboratory test abnormal, neoplasm progression. Somavert dosage: unknown. During the same period patient was treated with PROPRANOLOL, LEVOTHYROXINE, INDAPAMIDE. Patient recovered.Somavert Side Effects Report #4681829-1
Somavert side effect was reported by a Physician from on May 23, 2005. Male patient, 55 years of age, was diagnosed with acromegaly and was treated with Somavert. After drug was administered, patient experienced the following side effects: diplopia, eyelid ptosis, necrosis, neoplasm progression. Somavert dosage: 80 MG (80 MG, QD), SUBCUTANEOUS. During the same period patient was treated with LEVOTHYROXINE, HYDROCORTISONE. Patient recovered.
Somavert Side Effects Report #4707120-2
Somavert side effect was reported by a Physician from FRANCE on June 21, 2005. Male patient, 55 years of age, weighting 194.0 lb, was diagnosed with acromegaly and was treated with Somavert. After drug was administered, patient experienced the following side effects: diplopia, eyelid ptosis, neoplasm progression, tumour necrosis. Somavert dosage: 80 MG (80 MG, 1 IN 1 D), SUBCUTANEOUS. During the same period patient was treated with HYDROCORTISONE, LEVOTHYROXINE. Patient was hospitalized. Patient recovered.
Somavert and neoplasm progression 